OOIR: Observatory of International Research

Papers

(The H4-Index of npj Breast Cancer is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer	301
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies	178
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now	123
Triple negative breast cancer: Pitfalls and progress	122
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group	110
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer	103
Evolution of HER2-low expression from primary to recurrent breast cancer	94
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group	92
Immunotherapy in breast cancer: an overview of current strategies and perspectives	71
Immunotherapy for early triple negative breast cancer: research agenda for the next decade	68
Connected-UNets: a deep learning architecture for breast mass segmentation	63
ARe we there yet? Understanding androgen receptor signaling in breast cancer	58
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer	52
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	48
Large language model (ChatGPT) as a support tool for breast tumor board	48
Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis	46
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy	45
PARP inhibition in breast cancer: progress made and future hopes	43
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer	42
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer	40
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic	40
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment	39
The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients	38
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma	37
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer	34

Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge	34
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer	33
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis	33
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer	32
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort	32
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL	32
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups	31
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	31
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer	31